ScreenerHero

INO Inovio Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · inovio.com
1.155USD+2.21%Mkt Cap: 119.42M $P/E: —

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), c…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap119.42M USD
Enterprise Value88.17M USD
Revenue (TTM)0 USD
Gross Profit-48.49M USD
Net Income (TTM)-84.95M USD
Revenue/Share0.00 USD
Last Price1.155 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees112
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.57
PEG—
EV/EBITDA-1.13
EV/Revenue—
P/SInfinity
P/B21.32
EPS (TTM)-0.88
EPS (Forward)-0.44
52W Range
0.566627% of range2.720
52W High2.720 USD
52W Low0.5666 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-130000.00%
ROE-352.53%
ROA-114.31%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-88.63M USD
CapEx (TTM)285.70K USD
FCF Margin—
FCF Yield-28.35%
Net Debt-28.67M USD
Net Debt/EBITDA0.37
Balance Sheet
Debt/Equity0.39
Current Ratio1.00
Quick Ratio0.92
Book Value/Sh0.05 USD
Cash/Share0.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJan 25, 2024
Analyst Consensus
Rating—
Target (Mean)3.167 USD
Upside (mean)+174.2%
Target Range2.500 USD – 4.000 USD
2.500+174.2% to mean4.000
# Analysts3
Ownership
Shares Out.103.40M
Float95.79M
Insiders0.33%
Institutions46.02%
Short Interest
Short Ratio5.3d
Short % Float21.37%
Short % Out.19.27%
Shares Short19.92M
Short (prev mo.)19.96M
Technical
SMA 501.115 (+3.6%)
SMA 2001.344 (-14.1%)
Beta1.61
S&P 52W Chg16.45%
Avg Vol (30d)3.19M
Avg Vol (10d)2.56M
Technical Indicators
RSI (14)47.9
MACD-0.0001
MACD Signal0.0178
MACD Hist.-0.0179
BB Upper1.364 USD
BB Middle1.216 USD
BB Lower1.067 USD
BB Width24.40%
ATR (14)0.0860 USD
Vol Ratio (20d)1.01x